Biogen Inc

BIIB

$234.64

-23.3% last 12 months

PRIMECAP Management Holding value: $3.76 Billion Jim Simons Holding value: $255 Million Ray Dalio Holding value: $35.4 Million Ken Fisher Holding value: $26.7 Million Ken Griffin Holding value: $18.3 Million Jeremy Grantham Holding value: $13.3 Million Steven Cohen Holding value: $11.3 Million Joel Greenblatt Holding value: $4.56 Million Jefferies Group Holding value: $2.23 Million Paul Tudor Jones II Holding value: $0 John Paulson Holding value: $0 Richard Pzena Holding value: $0 Andreas Halvorsen Holding value: $0 Sands Capital Holding value: $0 First Eagle Investments Holding value: $0 Bill Miller Holding value: $0 Ron Baron Holding value: $0 David Abrams Holding value: $0 Mario Gabelli Holding value: $0 Cathie Wood Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Carl Icahn Holding value: $0 Michael Burry Holding value: $0 Warren Buffett Holding value: $0

Market Cap

$33.9 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$220.86 - $319.76

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

23.2x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $33.9 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $38.9 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -23.3%
52-Week High Highest share price in the last 52 weeks. $319.76
52-Week Low Lowest share price in the last 52 weeks. $220.86
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 145 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 1.12 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 23.2
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -21.89
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $10.07
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 3.45
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 2.37
Enterprise Value to Revenue Enterprise value divided by revenue 3.89
Enterprise Value to EBIT Enterprise Value divided by EBIT 20.46
Total Debt to Enterprise Value Total debt divided by enterprise value 0.19
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.5

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $9.99 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $7.51 Billion
EBIT Earnings before tax and interest payments. $1.9 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $1.46 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 14.63%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -106.0%
Return on Equity Equity divided by market cap. 10.09%
Return on Assets Indicates a company's profitability in relation to its total assets. 5.18%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 8.21%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Biogen Inc

CEO: Josephine Price

Employees: 7,300

Industry: Biological Product (except Diagnostic) Manufacturing

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Similar stocks

AMGEN Inc.
AMGEN Inc.
Gilead Sciences, Inc.
Gilead Sciences, Inc.
Abbvie Inc
Abbvie Inc
Pfizer Inc.
Pfizer Inc.
Johnson & Johnson
Johnson & Johnson
Acorda Therapeutics Inc
Acorda Therapeutics Inc
Sanofi - ADR
Sanofi - ADR
Bio-Rad Laboratories Inc. - Class A
Bio-Rad Laboratories Inc. - Class A
Illumina Inc
Illumina Inc
Qiagen NV
Qiagen NV

News

Biogen: LAQEMBI''s $10 Billion Potential

Biogen: LAQEMBI''s $10 Billion Potential

Biogen''s latest Alzheimer''s drug, Aduhelm, faced challenges after FDA approval. Click here to read why we still rate the BIIB stock as a ''Strong Buy''.

Seeking Alpha Seeking Alpha, 5 days ago
Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)

Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)

Biogen Inc. (NASDAQ:NASDAQ:BIIB) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ETCompany ParticipantsPriya Singhal - Head of…

Seeking Alpha Seeking Alpha, 6 days ago
Alzheimer''s Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others

Alzheimer''s Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others

Recent advancements in Alzheimer''s disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest ...

Benzinga Benzinga, 13 days ago
Biogen Inc (BIIB) —…—— CEO Christopher A. ...

Biogen Inc (BIIB) —…—— CEO Christopher A. ...

Biogen Inc (BIIB) 2022 CEO Christopher A. Viehbacher''s Shareholder Letter: Navigating Challenges and Seizing Opportunities

GuruFocus GuruFocus, 14 days ago
Never miss a trade
To improve your user experience we use cookies.